Covington Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Covington Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$119K	Sell	412 -75	-15%	-$21.6K	0.01%	434
2022 Q2	$137K	Sell	487 -38	-7%	-$10.2K	0.01%	415
2022 Q1	$137K	Buy	525 +181	+53%	+$43K	﹤0.01%	430
2021 Q4	$76K	Sell	344 -55	-14%	-$10.7K	﹤0.01%	486
2021 Q3	$72K	Buy	399 +30	+8%	+$5.86K	﹤0.01%	496
2021 Q2	$74K	Buy	369 +269	+269%	+$56.3K	﹤0.01%	486
2021 Q1	$21K	Buy	100 +25	+33%	+$5.49K	﹤0.01%	601
2020 Q4	$18K	Hold	75	–	–	﹤0.01%	598
2020 Q3	$20K	Hold	75	–	–	﹤0.01%	552
2020 Q2	$22K	Hold	75	–	–	﹤0.01%	544
2020 Q1	$18K	Sell	75 -34	-31%	-$7.8K	﹤0.01%	543
2019 Q4	$24K	Buy	109 +34	+45%	+$6.88K	﹤0.01%	574
2019 Q3	$13K	Sell	75 -20	-21%	-$3.54K	﹤0.01%	622
2019 Q2	$17K	Hold	95	–	–	﹤0.01%	577
2019 Q1	$17K	Buy	95 +20	+27%	+$3.69K	﹤0.01%	557
2018 Q4	$12K	Hold	75	–	–	﹤0.01%	609
2018 Q3	$14K	Sell	75 -116	-61%	-$20.7K	﹤0.01%	574
2018 Q2	$32K	Hold	191	–	–	﹤0.01%	483
2018 Q1	$31K	Hold	191	–	–	﹤0.01%	483
2017 Q4	$29K	Buy	191 +116	+155%	+$17.2K	﹤0.01%	526
2017 Q3	$11K	Buy	+75	New	+$11.3K	﹤0.01%	606

Other funds holding VRTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Covington Capital Management's VRTX Position: Q3 2022 in Review

Covington Capital Management reduced its Vertex Pharmaceuticals (VRTX) stake by 15% in Q3 2022, selling an estimated $21.6K and leaving 412 shares worth $119K. The position accounts for 0.01% of the portfolio, ranked #434.

Covington Capital Management first reported a position in VRTX in Q3 2017 and has held it in 21 quarters since. The position peaked at $137K in Q2 2022. 1,125 funds tracked by Wall St. Rank hold VRTX as of Q3 2022.

Covington Capital Management held 412 shares of Vertex Pharmaceuticals worth $119K as of Q3 2022.
Covington Capital Management sold 75 Vertex Pharmaceuticals shares in Q3 2022, an estimated $21.6K.
Vertex Pharmaceuticals made up 0.01% of Covington Capital Management's portfolio in Q3 2022, its #434 holding.
Covington Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2017 and has held it in 21 quarters since.
Covington Capital Management's Vertex Pharmaceuticals position peaked at $137K in Q2 2022.
1,125 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2022.

Based on Covington Capital Management's 13F filing for Q3 2022, filed 15 Nov 2022.